Dr. Matthew Gardner received his Ph.D. in Virology from Harvard University, and his undergraduate degree from Pennsylvania State University. Dr. Gardner has driven the eCD4-Ig project since he was a graduate student at Harvard Medical School. His study, published in Nature, demonstrated that eCD4-Ig delivered by an AAV vector can sustain protective concentrations of eCD4-Ig in blood for at least one year. Dr. Gardner’s research currently focuses on optimization of eCD4-Ig and the AAV vector needed to produce it in vivo after a single injection.
Dr. Gardner is the 2014 recipient of the Bernard N. Fields Prize, awarded to the M.D. or Ph.D. candidate within the Department of Microbiology & Immunobiology at Harvard Medical School who best exemplifies the virtues of intellectual creativity, collegiality, and compassion displayed by Bernard N. Fields as Professor and Chairman of the Department of Microbiology and Molecular Genetics.
Dr. Matthew Gardner received his Ph.D. in Virology from Harvard University, and his undergraduate degree from Pennsylvania State University. Dr. Gardner has driven the eCD4-Ig project since he was a graduate student at Harvard Medical School. His study, published in Nature, demonstrated that eCD4-Ig delivered by an AAV vector can sustain protective concentrations of eCD4-Ig in blood for at least one year. Dr. Gardner’s research currently focuses on optimization of eCD4-Ig and the AAV vector needed to produce it in vivo after a single injection.
Dr. Gardner is the 2014 recipient of the Bernard N. Fields Prize, awarded to the M.D. or Ph.D. candidate within the Department of Microbiology & Immunobiology at Harvard Medical School who best exemplifies the virtues of intellectual creativity, collegiality, and compassion displayed by Bernard N. Fields as Professor and Chairman of the Department of Microbiology and Molecular Genetics.